In addition, researchers have developed blocking monoclonal antibodies against SAA1 as promising novel targets for the treatment of hematological malignancies to inhibit SAA1’s potent oncogenic effects on malignant HSCs and to examine its potential therapeutic activity. Here, SAA1 is linked to hematologic disorder.